Nektar Therapeutics is a stage-clinical biopharmaceutical company. The Сompany develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify the chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. Nektar Therapeuticsэ R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease, and chronic pain.
Type | Public | |
Founded | 1990 | |
HQ | San Francisco, CA, US | Map |
Website | nektar.com | |
Employee Ratings | More |
USD | |
---|---|
Revenue (Q3, 2020) | 5.7m |
Market capitalization (15-Jan-2021) | 3.0b |
Closing stock price (15-Jan-2021) | 17.0 |
Cash (30-Sept-2020) | 55.8m |
EV | 3.1b |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | Y, 2015 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 71.5m | 81.2m | 148.9m | 200.7m | 230.8m | 230.8m | 165.4m | 307.7m | 1.2b | 114.6m |
Revenue growth, % | 35% | 15% | (28%) | |||||||
Cost of goods sold | 21.9m | 30.4m | 38.5m | 28.5m | 34.1m | 34.1m | 30.2m | 30.5m | 24.4m | 21.4m |
Gross profit | 49.6m | 50.8m | 110.4m | 172.2m | 196.7m | 196.7m | 135.2m | 277.2m | 1.2b | 93.2m |
USD | Q1, 2011 | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 11.3m | 17.3m | 27.1m | 17.9m | 23.7m | 18.4m | 23.0m | 33.9m | 60.9m | 19.8m | 28.5m | 132.9m | 108.8m | 22.7m | 60.0m | 58.9m | 32.8m | 36.3m | 24.7m | 34.6m | 152.9m | 38.0m | 1.1b | 27.8m | 28.2m | 23.3m | 29.2m | 50.6m | 5.5m | 5.7m |
Cost of goods sold | 3.3m | 8.1m | 5.0m | 8.7m | 7.2m | 7.2m | 11.7m | 5.0m | 12.9m | 7.9m | 5.1m | 9.2m | 8.4m | 10.5m | 6.8m | 8.9m | 7.7m | 7.0m | 6.1m | 9.0m | 5.7m | 6.6m | 5.4m | 5.0m | 4.9m | 3.8m | ||||
Gross profit | 8.0m | 9.2m | 22.0m | 9.2m | 16.5m | 11.2m | 11.3m | 28.9m | 48.0m | 11.9m | 23.4m | 123.7m | 100.4m | 12.1m | 53.2m | 50.0m | 25.1m | 29.3m | 18.6m | 25.6m | 147.3m | 31.4m | 22.8m | 18.3m | 24.3m | 46.8m | ||||
Gross profit Margin, % | 71% | 53% | 81% | 51% | 70% | 61% | 49% | 85% | 79% | 60% | 82% | 93% | 92% | 54% | 89% | 85% | 76% | 81% | 75% | 74% | 96% | 83% | 81% | 78% | 83% | 92% |
USD | Q1, 2011 | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 22.5m | 11.6m | 43.0m | 148.5m | 136.2m | 10.3m | 28.5m | 41.4m | 65.4m | 32.4m | 30.7m | 32.0m | 129.5m | 20.9m | 18.8m | 72.5m | 55.7m | 63.3m | 23.5m | 16.1m | 38.0m | 34.8m | 911.1m | 222.3m | 106.8m | 85.4m | 81.2m | 227.0m | 58.2m | 55.8m |
Accounts Receivable | 2.2m | 8.5m | 12.9m | 10.8m | 11.4m | 3.9m | 3.6m | 6.0m | 4.6m | 1.9m | 3.0m | 46.1m | 2.9m | 3.7m | 3.0m | 39.7m | 27.8m | 14.2m | 1.6m | 4.1m | 3.3m | 15.6m | 35.3m | 31.9m | 42.9m | 37.3m | 41.2m | 42.0m | 47.2m | 42.9m |
Prepaid Expenses | 6.9m | 7.9m | 7.6m | 13.6m | 9.3m | 7.0m | 8.8m | 6.0m | 4.8m | 6.0m | 4.6m | 4.7m | 6.1m | 8.8m | 5.2m | 5.6m | 5.4m | 4.0m | 7.9m | 7.5m | 13.3m | 13.1m | 34.9m | 12.5m | 19.4m | 13.2m | 15.2m | |||
Inventories | 11.7m | 9.8m | 10.7m | 14.1m | 14.7m | 16.8m | 18.4m | 20.5m | 15.1m | 12.9m | 14.1m | 11.7m | 12.5m | 10.1m | 10.4m | 11.3m | 10.3m | 10.8m | 13.0m | 11.0m | 13.7m | 10.7m | 11.9m | 13.3m | 11.8m | 13.2m | 13.7m | 14.3m | 12.6m | 12.9m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
Net Income | (134.0m) | (171.9m) | (162.0m) | (53.9m) | (81.2m) | (153.5m) | (96.7m) | 681.3m | (440.7m) |
Depreciation and Amortization | 15.0m | 14.5m | 14.3m | 12.9m | 12.9m | 15.4m | 14.7m | 10.9m | 13.2m |
Inventories | (5.4m) | (5.6m) | 4.8m | 500.0k | 1.6m | 237.0k | 383.0k | (655.0k) | (1.3m) |
Accounts Payable | (3.4m) | (122.0k) | 6.2m | (6.4m) | (412.0k) | 518.0k | 2.1m | 971.0k | 13.0m |
USD | Q1, 2011 | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (36.0m) | (72.4m) | (96.5m) | (41.1m) | (75.4m) | (118.9m) | (55.1m) | (97.8m) | (114.4m) | (46.2m) | (78.8m) | (8.2m) | 33.8m | (18.8m) | (27.0m) | (19.5m) | (68.1m) | (111.3m) | (63.9m) | (123.7m) | (62.9m) | (95.8m) | 875.7m | 779.5m | (118.5m) | (228.4m) | (327.2m) | (138.7m) | (218.7m) | (327.2m) |
Depreciation and Amortization | 3.9m | 7.6m | 11.4m | 3.5m | 7.0m | 10.6m | 3.6m | 7.3m | 10.9m | 3.3m | 6.5m | 9.7m | 3.0m | 5.8m | 9.1m | 3.7m | 7.6m | 11.5m | 4.0m | 8.3m | 12.1m | 2.5m | 5.1m | 7.8m | 3.1m | 6.1m | 9.6m | 4.5m | 7.7m | 10.9m |
Inventories | (4.4m) | (2.5m) | (3.4m) | (1.5m) | (2.1m) | 4.1m | (112.0k) | (2.2m) | 3.2m | 580.0k | (659.0k) | 1.8m | 441.0k | 2.8m | 2.6m | 96.0k | 1.1m | 592.0k | (1.9m) | 101.0k | (2.5m) | 51.0k | (1.2m) | (2.6m) | (397.0k) | (1.8m) | (2.3m) | (1.7m) | 81.0k | (227.0k) |
Accounts Payable | (2.9m) | (3.1m) | (4.2m) | (1.3m) | 80.0k | (401.0k) | 1.4m | 2.6m | 697.0k | (6.1m) | (1.8m) | (3.7m) | 2.2m | (10.0k) | (525.0k) | (34.0k) | 17.0k | 4.8m | 4.1m | 3.2m | 5.7m | 6.5m | 5.8m | 2.6m | 5.2m | 3.5m | 16.1m | 2.7m | 425.0k | (3.3m) |
USD | Q1, 2011 |
---|---|
Financial Leverage | 2.5 x |
Nektar Therapeutics has 1.23k Twitter Followers. The number of followers has decreased 0.2% month over month and increased 1.1% quarter over quarter
503
Tweets
361
Following
1.2k
Followers
1
Tweets last 30 days
1
Avg. likes per Tweet
100%
Tweets with engagement
When was Nektar Therapeutics founded?
Nektar Therapeutics was founded in 1990.
Who are Nektar Therapeutics key executives?
Nektar Therapeutics's key executives are Jeff Ajer, Robert B. Chess and Gil M. Labrucherie.
How many employees does Nektar Therapeutics have?
Nektar Therapeutics has 618 employees.
What is Nektar Therapeutics revenue?
Latest Nektar Therapeutics annual revenue is $114.6 m.
What is Nektar Therapeutics revenue per employee?
Latest Nektar Therapeutics revenue per employee is $185.5 k.
Who are Nektar Therapeutics competitors?
Competitors of Nektar Therapeutics include Mirati Therapeutics, CytomX Therapeutics and Calithera Biosciences.
Where is Nektar Therapeutics headquarters?
Nektar Therapeutics headquarters is located at 455 Mission Bay Boulevard South, San Francisco, San Francisco.
Where are Nektar Therapeutics offices?
Nektar Therapeutics has offices in San Francisco, Huntsville and Secunderabad.
How many offices does Nektar Therapeutics have?
Nektar Therapeutics has 3 offices.
Receive alerts for 300+ data fields across thousands of companies